Document:

EX-10.16

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit
10.16 
 AMENDMENT NO. 1 

TO THE 
 EXCLUSIVE LICENSE
AGREEMENT 
 This AMENDMENT NO. 1 TO THE EXCLUSIVE
LICENSE AGREEMENT (this “Amendment”), dated as of October 22, 2012 (the “Amendment Effective Date”), is made by and between AMGEN
INC., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and NINA BIOTHERAPEUTICS, INC.,
a Delaware corporation (“Licensee”). 
 WHEREAS, Amgen and Licensee entered into that certain Exclusive License Agreement,
dated as of September 7, 2012 (the “Agreement”), pursuant to which Licensee received certain rights to develop and commercialize the Products (as defined in the Agreement); 

WHEREAS, Amgen and Licensee wish to update certain portions of the Agreement. 

NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the Parties hereto agree to amend the Agreement as
follows: 
 ARTICLE 1 - AMENDMENT 

Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement. 

 

	1.1	Correction of Licensee Name. All references in the Agreement to “Nina Biosciences” are hereby amended to refer instead to “Nina Biotherapeutics”. 

 

	1.2	Amendments to Section 1.3 of Licensed Know-How Schedule (AMG 842 and M43 Research Analytical Assays, Methods and Materials). The following table shall be appended to the end of the Section under the
heading “Additional Materials”: 

  

							
	 Material/ Reagent
	  	 Lot. No./Batch ID
	  	 Expiration Date
	  	 Amount Provided

	[*]	  	[*]	  	[*]	  	[*]

  

	1.3	Amendment of Section 1.5 of Licensed Know-How Schedule (Pending Licensed Know-How). Section 1.5 of the Licensed Know-How Schedule shall be replaced in its entirety with the following:
“[Section intentionally left blank.]” 

  

	1.4	Amendment of Press Release Schedule. The Press Release Schedule shall be replaced in its entirety with the revised press release attached to this Amendment as Schedule 1. 

  
 1. 

 ARTICLE 2 - REFERENCE TO AND EFFECT ON THE AGREEMENT 

 

	2.1	Reference to Agreement. Upon and after the effectiveness of this Amendment, each reference in the Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import
referring to the Agreement shall mean and be a reference to the Agreement as modified and amended hereby. 

  

	2.2	Effectiveness of Amendment. Upon execution and delivery of this Amendment by both Parties, the amendments set forth above shall be effective as of the Amendment Effective Date. Except as specifically
amended above, the Agreement is and shall continue to be in full force and effect and is hereby in all respects ratified and confirmed and shall constitute the legal, valid, binding and enforceable obligations of the Parties. 

 

	2.3	No Waiver. The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of either Party under the Agreement, nor constitute a waiver of any
provision of the Agreement. 

 ARTICLE 3 - MISCELLANEOUS 

 

	3.1	Governing Law. This Amendment shall be governed by and construed in accordance with the laws of [*], as applied to agreements executed and performed entirely within [*], without regard to any applicable
principles of conflicts of law. Each of the Parties hereby irrevocably and unconditionally consents to the exclusive jurisdiction of the courts of [*] for any matter arising out of or relating to this Amendment and the transactions contemplated
hereby. 

  

	3.2	Headings. The heading for each article and section in this Amendment has been inserted for convenience of reference only and is not intended to limit or expand on the meaning of the language contained in
the particular article or section. 

  

	3.3	Counterparts. This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 [Signature page follows] 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

2. 

 IN WITNESS THEREOF, duly authorized representatives of the Parties hereto have executed this Amendment as of the
date first set forth above. 
  

									
	Nina Biotherapeutics, Inc.	 		 	Amgen Inc.
					
	By:	 	 /s/ Isaac Ciechanover
	 		 	By:	 	 /s/ Jonathan Peacock

		 	Name: Isaac Ciechanover	 		 		 	Name: Jonathan Peacock
		 	Title: CEO	 		 		 	Title: Executive Vice President & CFO

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

3. 

 Schedule 1 

Revised Press Release 
 Amgen and KPCB
Partner to Create Atara Biotherapeutics 
 AMGEN AND KLEINER PERKINS CAUFIELD & BYERS PARTNER TO CREATE NEW SPIN-OUT BIOTECH COMPANY 

Amgen to License Pipeline Assets to Newly Formed Company 

THOUSAND OAKS, Calif. and MENLO PARK, Calif. (Oct. 25, 2012) – Amgen and Kleiner Perkins Caufield & Byers (KPCB) today announced the formation of
Atara Biotherapeutics, (www.atarabio.com), a new drug development company with a focus on innovative therapies for patients with chronic diseases in therapeutic areas including nephrology and oncology. Atara Biotherapeutics will have licenses
to six Amgen assets, which are in various stages of development, ranging from preclinical to Phase 1. Financial terms of the transaction are not being disclosed. 

Atara Biotherapeutics will be financed initially by KPCB, and Isaac Ciechanover, M.D., a former partner at KPCB, will serve as the president and chief
executive officer. Amgen will have a minority equity interest in Atara Biotherapeutics. 
 “Amgen is excited to partner with KPCB to help advance
molecules in Amgen’s pipeline that have the potential to treat serious illnesses,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “With facilities in both the Bay Area and near Amgen’s
Thousand Oaks campus, Atara Biotherapeutics will provide the opportunity to further foster biotechnology innovation in Amgen’s communities.” 

“We look forward to building on Amgen’s research to bring a promising group of therapeutics to patients with serious illnesses,” said
Ciechanover. 
 About Amgen  
 Amgen discovers,
develops, manufactures and delivers innovative human therapeutics. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 

 
A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab to manufacturing plant to
patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad
pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com. Follow us on
www.twitter.com/amgen. 
 About Kleiner Perkins Kleiner Perkins Caufield & Byers (KPCB) has backed entrepreneurs in more than 500
ventures leading to 150 IPOs, 350,000 jobs and a deep strategic network. The firm has helped build pioneering companies like Align, Amazon, Electronic Arts, Genentech, Genomic Health, Google, Intuit, Juniper Networks, Netscape, Symantec, VeriSign
and WebMD. KPCB partners serve on the boards of Amazon, Apple, Bloom Energy, Flipboard, Foundation Medicine, Google, Hewlett-Packard, Nest, Square, Tesaro and Zynga, among others. KPCB accelerates the success of entrepreneurs with a team of partners
delivering company-building services including strategy, operational scaling, recruiting, business development and product delivery. The firm invests in all stages from seed and incubation to growth companies. KPCB operates from offices in Menlo
Park, San Francisco, Shanghai and Beijing. http://www.kpcb.com. 
 Forward-Looking Statements This news release contains forward-looking
statements that involve significant risks and uncertainties, including those discussed below and others that can be found in Amgen’s Form 10-K for the year ended Dec. 31, 2011, and in its periodic reports on Form 10-Q and Form 8-K. Amgen is
providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. 

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Amgen’s results may be affected by
Amgen’s ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched
products, competition from other products (domestic or foreign), difficulties or delays in manufacturing its products. In addition, sales of Amgen products are affected by reimbursement policies imposed by third-party payors, including governments,
private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others’ regulations and reimbursement policies may affect the development, usage and pricing of Amgen products. Furthermore, Amgen’s research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen or others could identify safety, side effects or manufacturing problems with Amgen products after they are on the market. Amgen’s
business may be impacted by government investigations, litigation and products liability claims. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be
challenged, invalidated or circumvented by its competitors. Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current and future products and limits on supply may constrain sales
of certain of its current products and product candidate development. In addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products. Discovery or
identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.
Further, some raw materials, medical devices and component parts for Amgen products are supplied by sole third-party suppliers. Amgen’s business performance could affect or limit the ability of its Board of Directors to declare a dividend or
its ability to pay a dividend or repurchase its common stock. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.17

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit
10.17 
 AMENDMENT NO. 2 

TO THE 
 EXCLUSIVE LICENSE
AGREEMENT 
 This AMENDMENT NO. 2 TO THE EXCLUSIVE
LICENSE AGREEMENT (this “Amendment”), dated as of September 7, 2012 (the “Amendment Effective Date”), is made by and between AMGEN
INC., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and NINA BIOTHERAPEUTICS, INC.,
a Delaware corporation having an address of 3260 Bayshore Blvd, Brisbane, California 94005 (“Licensee”). 
 WHEREAS,
Amgen and Licensee entered into that certain Exclusive License Agreement, dated as of September 7, 2012 and amended as of October 22, 2012 (the “Agreement”), pursuant to which Licensee received certain rights to
develop and commercialize the Products (as defined in the Agreement); 
 WHEREAS, Amgen and Licensee wish to update certain portions of the
Agreement. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the Parties hereto agree to amend the
Agreement as follows: 
 ARTICLE 1 - AMENDMENT 

Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement. 

 

	1.1	Amendment of Section 5.2. The third sentence in Section 5.2 is hereby amended and restated in its entirety as follows: 

“In addition to the obligations of Company to use Commercially Reasonable Efforts, if Company, its Affiliates and/or their respective
Sub-licensees have not [*], Company shall promptly (but in no event later than [*] after each such applicable date) notify Amgen in writing of such failure to achieve such event (a “Specified Diligence Failure”) in a timely manner
(the “Diligence Notice”); provided that if Company either (A) fails to timely [*] despite its good faith efforts to do so or (B) has a Specified Diligence Failure as a result of [*] as required under [*], then the
deadline described above shall be equitably extended to account for [*] to comply therewith (provided, in the case of a failure under clause (A), such equitable extension shall [*]).” 

	1.2	Amendment of Products Schedule. The sequence for AMG 842 described on the Products Schedule to the Agreeement is hereby amended and restated in its entirety as set forth on Schedule 1 to this Amendment.

 ARTICLE 2 – REFERENCE TO AND EFFECT ON THE AGREEMENT 

 

	2.1	Reference to Agreement. Upon and after the effectiveness of this Amendment, each reference in the Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import
referring to the Agreement shall mean and be a reference to the Agreement as modified and amended hereby. 

  

	2.2	Effectiveness of Amendment. Upon execution and delivery of this Amendment by both Parties, the amendments set forth above shall be effective as of the Amendment Effective Date. Except as specifically
amended above, the Agreement is and shall continue to be in full force and effect and is hereby in all respects ratified and confirmed and shall constitute the legal, valid, binding and enforceable obligations of the Parties. 

 

	2.3	No Waiver. The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of either Party under the Agreement, nor constitute a waiver of any
provision of the Agreement. 

 ARTICLE 3 – MISCELLANEOUS 

 

	3.1	Governing Law. This Amendment shall be governed by and construed in accordance with the laws of [*], as applied to agreements executed and performed entirely within [*], without regard to any applicable
principles of conflicts of law. Each of the Parties hereby irrevocably and unconditionally consents to the exclusive jurisdiction of the courts of [*] for any matter arising out of or relating to this Amendment and the transactions contemplated
hereby. 

  

	3.2	Headings. The heading for each article and section in this Amendment has been inserted for convenience of reference only and is not intended to limit or expand on the meaning of the language contained in
the particular article or section. 

  

	3.3	Counterparts. This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 [Signature page follows] 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
 2 

 IN WITNESS THEREOF, duly authorized representatives of the Parties hereto have executed this Amendment as of the
date first set forth above. 
  

									
	NINA BIOTHERAPEUTICS, INC.	  		  	AMGEN INC.
					
	By:	  	 /s/ Isaac Ciechanover
	  		  	By:	  	 /s/ David Piacquad

	Name:	  	Isaac Ciechanover	  		  	Name:	  	David Piacquad
	Title:	  	CEO	  		  	Title:	  	 Senior Vice President,
 Business
Development

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
 3 

 Schedule 1 to Amendment No. 2 to the Exclusive License Agreement 

Schedule 
 Products

 [*] 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]